Biodesix expects 2026 sales to crack $100M

LOUISVILLE — Biodesix Inc. (Nasdaq: BDSX), a life-sciences company that specializes in developing tools to detect lung disease, improved its top and bottom lines in both the fourth quarter of last year and the full 2025 fiscal year. 

The company posted total sales of $28.8 million in the most-recent period, good for a 41% year-over-year bump, and $88.5 million in fiscal 2025, an increase of 24%. 

Biodesix’s net loss in the fourth quarter was $4 million and $35.3 million for the full year. Those are year-over-year improvements of 52% and 18%, respectively. 

“We exceeded the high end of our revenue guidance by delivering 41% growth, and for the first time ever, achieved Adjusted EBITDA positivity in the quarter demonstrating the strength of our operating leverage and gross margins, which have become a hallmark of Biodesix performance,” Biodesix CEO Scott Hutton said in a prepared statement. “In 2025, we accelerated the growth of our lung-focused commercial strategy, expanded our pipeline, announced new partnerships, grew our development services offering, and presented clinical data on our on-market and pipeline products.”

Looking ahead, Biodesix is offering revenue guidance in the range of $106 million to $112 million for fiscal 2026.

At 11:45 a.m. Friday, Biodesix’s stock was trading at $15.01, up 5.56% on the day and 35.47% over the past month. 

Share on Facebook on LinkedIn